Data upload for Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples

  • Daniel Saarela (Aligning Science Across Parkinson's (ASAP) (Creator)
  • Pawel Lis (Creator)
  • Wentao Dong (Creator)
  • Eshaan Rawat (Stanford University) (Creator)
  • Rotimi Fasimoye (Creator)
  • Enrico Bagnoli (Creator)
  • Raja Nirujogi (Creator)
  • Matthew Jaconelli (Creator)
  • Sara Gomes Moreira (Creator)
  • Karolina Zeneviciute (Creator)
  • Judith Jans (Utrecht University) (Creator)
  • Peter van Hasselt (Utrecht University) (Creator)
  • Lena Westermann (University Medical Center Hamburg-Eppendorf) (Creator)
  • Angela Schulz (University Medical Center Hamburg-Eppendorf) (Creator)
  • Christian Posern (University Medical Center Hamburg-Eppendorf) (Creator)
  • Fanni A. Boros (Creator)
  • Margriet A. Huisman (Creator)
  • Sophie Glendinning (Creator)
  • Frederike Zunke (Creator)
  • Dario Alessi (Creator)
  • Monther Abu-Remaileh (Creator)
  • Esther Sammler (Creator)

Dataset

Description

Lysosomes are implicated in a wide spectrum of human diseases including monogenic lysosomal storage disorders (LSDs), age-associated neurodegeneration and cancer. Profiling lysosomal content using tag-based lysosomal immunoisolation (LysoTagIP) in cell and animal models allowed major discoveries in the field, however, studying lysosomal dysfunction in human patients remains a challenge. Here, we report the development of the tagless LysoIP method to enable rapid enrichment of lysosomes, via immunoisolation, using the endogenous integral lysosomal membrane protein TMEM192, directly from clinical samples and human cell lines. Isolated lysosomes are intact and suitable for subsequent multimodal omics analyses. To validate the utility of our approach, we employed the tagless LysoIP to enrich lysosomes from peripheral blood mononuclear cells (PBMCs) derived from fresh blood of patients with CLN3 Batten disease, a neurodegenerative LSD. Metabolic profiling of isolated lysosomes showed massive accumulation of glycerophosphodiesters (GPDs) in patients’ lysosomes. Interestingly, a patient with a milder phenotype and genotype, displayed lower accumulation of lysosomal GPDs, consistent with their potential role as disease biomarkers. Altogether, the tagless LysoIP provides a framework to study native lysosomes from patient samples, identify novel biomarkers and discover human-relevant disease mechanisms.
Date made available15 Jul 2024
PublisherZenodo

Cite this